Amphastar Pharmaceuticals
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
| Company type | Public |
|---|---|
Traded as |
|
| Headquarters | Rancho Cucamonga, California, United States |
Key people |
|
| Revenue | US$ 644.4 million (2023) |
| US$ 196.9 million (2023) | |
Net income | US$ 137.5 million (2023) |
| Total assets | US$ 741.9 million (2022) |
| Total equity | US$ 528.6 million (2022) |
Number of employees | 1,615 |
| Website | Amphastar.com |
| Footnotes / references | |
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.
In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn.